In the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), a follicular neoplasm reported as Bethesda Category IV carries a malignancy risk of approximately:

• A 1–4%
• B 45–60%
• C 10–40% ✓
• D More than 90%

Explanation

Bethesda Category IV (Follicular Neoplasm / Suspicious for Follicular Neoplasm) carries a malignancy risk of approximately 10–40% in the revised 2017 TBSRTC classification (reflecting the reclassification of non-invasive follicular thyroid neoplasm with papillary-like nuclear features [NIFTP]). The standard management is a diagnostic hemithyroidectomy to allow histological assessment of capsular/vascular invasion — which cannot be determined by FNA cytology alone.

Reference: Bailey & Love's Short Practice of Surgery, 27th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.